Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer

Epigenetics

Volumn 6, Issue 6, 2011, Pages 710-719

  Muscarella, Lucia Anna ^a   Parrella, Paola ^a   D'Alessandro, Vito ^b   la Torre, Annamaria ^a   Barbano, Raffaela ^a   Fontana, Andrea ^c   Tancredi, Antonio ^d,e   Guarnieri, Vito ^f   Balsamo, Teresa ^a   Coco, Michelina ^a   Copetti, Massimiliano ^c   Pellegrini, Fabio ^c,g   de Bonis, Patrizia ^f   Bisceglia, Michele ^h   Scaramuzzi, Gerardo ^d   Maiello, Evaristo ⁱ   Valori, Vanna Maria ⁱ   Merla, Giuseppe ^f   Vendemiale, Gianluigi ^b,j   Fazio, Vito Michele ^a,k  

^a Oncology Laboratory   (Italy)

^b Internal Medicine and Nuclear Medicine Unit   (Italy)

^c Unit of Biostatistics   (Italy)

^d Thoracic Surgery Unit   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f Medical Genetics Unit Polyclinic sant'Orsola Malpighi   (Italy)

^g Consorzio Mario Negri Sud ^*  (Italy)

^h Department of Pathology ^*  (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j UNIVERSITY OF FOGGIA   (Italy)

^k UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

KEAP1; Methylation; Mutation; NRF2; NSCLC; Outcome

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; DEREGULATION; DISEASE COURSE; EPIGENETICS; FEMALE; GENE INACTIVATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; METHYLATION; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SOMATIC MUTATION; TREATMENT RESPONSE;

EID: 79958702879     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.6.15773     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360; PMID: 14736927.
4. Bordoni R. Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 2008; 13:945-953; PMID: 18779538.
5. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34:176-188; PMID:19321346; DOI: 10.1016/j.tibs.2008.12.008.
6. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47:89-116; PMID: 12963964; DOI: 10.1146/annurev.pharmtox.46.120604.141046.
7. Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos 2009; 30:345-355; PMID: 19725016; DOI: 10.1002/bdd.680.
8. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38:769-789; PMID: 17145701; DOI: 10.1080/03602530600971974.
9. MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009; 30:1571-1580; PMID: 19608619; DOI: 10.1093/carcin/bgp176.
10. Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 2008; 260:96-108; PMID:18036733; DOI: 10.1016/j.canlet.2007.10.022.
11. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 2009; 620:138-144; PMID: 19698707; DOI: 10.1016/j.ejphar.2009.08.022.
12. Yu X, Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat Res 2005; 591:93-102; PMID:16054659; DOI: 10.1016/j.mrfmmm.2005.04.017.
13. Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006; 27:1094-1100; PMID:16959318; DOI: 10.1016/j.neuro.2006.07.019.
14. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smokeinduced emphysema in mice. J Clin Invest 2004; 114:1248-1259; PMID: 15520857; DOI: 10.1172/JCI200421146.
15. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocininduced diabetic nephropathy. Diabetes 59:850-860; PMID: 20103708; DOI: 10.2337/db09-1342.
16. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001; 98:3410-3415; PMID: 11248092; DOI: 10.1073/pnas.051618798.
17. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58:262-270; PMID: 18838122; DOI: 10.1016/j.phrs.2008.09.003.
18. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006; 21:689-700; PMID: 16507366; DOI: 10.1016/j.molcel.2006.01.013.
19. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3:420; PMID: 17020408; DOI: 10.1371/journal.pmed.0030420.
20. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68:1303-1309; PMID:18316592; DOI: 10.1158/0008-5472.CAN-07-5003.
21. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135:1358-1368; PMID: 18692501; DOI: 10.1053/j.gastro.2008.06.082.
22. Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007; 362:816-821; PMID: 17822677; DOI: 10.1016/j.bbrc.2007.08.051.
23. Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 2009; 47:1619-1631; PMID:19751820; DOI: 10.1016/j.freeradbiomed.2009.09.006.
24. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008; 68:7975-7984; PMID: 18829555; DOI: 10.1158/0008-5472.CAN-08-1401.
25. Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, et al. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 2008; 60:47-56; PMID: 18006113; DOI: 10.1016/j.lungcan.2007.09.021.
26. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373:151-154; PMID:18555005; DOI: 10.1016/j.bbrc.2008.06.004.
27. Muscarella LA, Barbano R, D'Angelo V, Copetti M, Coco M, Balsamo T, et al. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 2011; 6:307-315; PMID: 21173573 DOI:10.4161/epi.
28. Padmanabhan B, Nakamura Y, Yokoyama S. Structural analysis of the complex of Keap1 with a prothymosin alpha peptide. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008; 64:233-238; PMID: 18391415; DOI:10.1107/S1744309108004995.
29. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009; 25:1189-1191; PMID: 19151095; DOI: 10.1093/bioinformatics/btp033.
30. Clamp M, Cuff J, Searle SM, Barton GJ. The Jalview Java alignment editor. Bioinformatics 2004; 20:426-427; PMID: 14960472. DOI: 10.1093/bioinformatics/btg430.
31. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31:3812-3814. PMID: 12824425.
32. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31:3568-3571. PMID: 12824367.
33. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol 1997; 4:311-323. PMID: 9278062.
34. Sunyaev S, Ramensky V, Koch I, Lathe W, 3rd, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001; 10:591-597; PMID: 11230178. DOI: 10.1093/hmg/10.6.591.
35. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10:5349-5354. PMID: 15328171; DOI: 10.1158/1078-0432.CCR-04-0555.
36. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16:3743-3753. PMID: 20534738; DOI: 10.1158/1078-0432.CCR-09-3352.
37. Bardwell VJ, Treisman R. The POZ domain: a conserved protein-protein interaction motif. Genes Dev 1994; 8:1664-1677; PMID: 7958847; DOI: 10.1101/gad.8.14.1664.
38. Zipper LM, Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 2002; 277:36544-36552. PMID:12145307; DOI: 10.1074/jbc.M206530200.
39. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005; 25:162-171. PMID: 15601839; DOI: 10.1128/MCB.25.1.162-71.2005.
40. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24:7130-7139. PMID: 15282312; DOI: 10.1128/MCB.24.16.7130-9.2004.
41. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 2000; 20:3633-3639. PMID: 10779353.
42. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer 1975-2002, featuring populationbased trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407-1427. PMID: 16204691; DOI: 10.1093/jnci/dji289.
43. Mulshine JL, Jablons DM. Volume CT for diagnosis of nodules found in lung-cancer screening. N Engl J Med 2009; 361:2281-2282.
44. Marcus PM. Lung cancer screening: an update. J Clin Oncol 2001; 19:83-86; PMID: 11560979.
45. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95:11891-11896. PMID: 9751761.
46. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91:332-339. PMID: 10050866; DOI: 10.1093/jnci/91.4.332.
47. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60:5954-5958. PMID: 11085511.
48. Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004; 10:2284-2288. PMID: 15073103; DOI: 10.1158/1078-0432.CCR-1111-3.
49. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum and plasma DNA of patients with lung cancer. Cancer Res 2002; 62:371-375. PMID: 11809682.
50. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, et al. High RAD51 mRNA expression characterize ER-positive/PR-negative breast cancers and is associated with patient's outcome. Int J Cancer PMID: 21064098. DOI: 10.1002/ijc.25736.
51. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA. Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 2001; 127:64-70. PMID: 11408068.
52. Takahashi T, Sonobe M, Menju T, Nakayama E, Mino N, Iwakiri S, et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J Surg Oncol 2010; 101:500-506. PMID:20213688. DOI: 10.1002/jso.21520.